Analyst Ratings for Verrica Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Verrica Pharmaceuticals (NASDAQ:VRCA) in the last quarter, with 4 bullish and 1 somewhat bullish ratings. The average 12-month price target for the company is $11.4, which has increased by 3.64% over the past month.
August 10, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verrica Pharmaceuticals has received positive ratings from analysts, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings often influence investor sentiment. The bullish ratings and increased price target for Verrica Pharmaceuticals indicate a positive outlook for the company, which could lead to increased demand for the stock and a potential rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100